Syngene International Limited (SYNGENE.NS)
INR 849.5
(-1.16%)
INR 849.5
(-1.16%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 2.38 Billion INR | -28.34% |
| 2022 | 3.32 Billion INR | 85.51% |
| 2021 | 1.79 Billion INR | 201.01% |
| 2020 | 596 Million INR | 136.51% |
| 2019 | 252 Million INR | -41.94% |
| 2018 | 434 Million INR | -49.53% |
| 2017 | 860 Million INR | 167.08% |
| 2016 | 322 Million INR | -14.59% |
| 2015 | 377 Million INR | -1.82% |
| 2014 | 384 Million INR | 157.72% |
| 2013 | 149 Million INR | -16.76% |
| 2012 | 179 Million INR | 20.13% |
| 2011 | 149 Million INR | 136.51% |
| 2010 | 63 Million INR | -26.74% |
| 2009 | 86 Million INR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 1.98 Billion INR | -16.77% |
| 2024 Q2 | 1.7 Billion INR | -14.11% |
| 2023 Q4 | 2.38 Billion INR | -9.97% |
| 2023 Q1 | 3.25 Billion INR | -2.19% |
| 2023 Q2 | 3.2 Billion INR | -1.57% |
| 2023 Q3 | 2.64 Billion INR | -17.32% |
| 2023 FY | 2.38 Billion INR | -28.34% |
| 2022 Q3 | 3.57 Billion INR | 34.01% |
| 2022 Q4 | 3.32 Billion INR | -6.88% |
| 2022 FY | 3.32 Billion INR | 85.51% |
| 2022 Q1 | 2.27 Billion INR | 26.64% |
| 2022 Q2 | 2.66 Billion INR | 17.39% |
| 2021 FY | 1.79 Billion INR | 201.01% |
| 2021 Q2 | 1.65 Billion INR | 25.86% |
| 2021 Q4 | 1.79 Billion INR | -17.21% |
| 2021 Q3 | 2.16 Billion INR | 30.94% |
| 2021 Q1 | 1.31 Billion INR | 120.64% |
| 2020 Q3 | - INR | -100.0% |
| 2020 FY | 596 Million INR | 136.51% |
| 2020 Q2 | 582 Million INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q4 | 596 Million INR | 0.0% |
| 2019 Q4 | 252 Million INR | 0.0% |
| 2019 FY | 252 Million INR | -41.94% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q2 | 511 Million INR | 0.0% |
| 2018 FY | 434 Million INR | -49.53% |
| 2018 Q2 | 730 Million INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 Q4 | 434 Million INR | 0.0% |
| 2017 Q4 | 860 Million INR | 19.44% |
| 2017 Q2 | 751 Million INR | 0.0% |
| 2017 FY | 860 Million INR | 167.08% |
| 2017 Q3 | 720 Million INR | -4.13% |
| 2017 Q1 | - INR | -100.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q2 | 354 Million INR | 0.0% |
| 2016 FY | 322 Million INR | -14.59% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q4 | 322 Million INR | 0.0% |
| 2015 FY | 377 Million INR | -1.82% |
| 2015 Q3 | 490 Million INR | 12.83% |
| 2015 Q2 | 434.3 Million INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q4 | 377 Million INR | -23.06% |
| 2014 Q4 | 384 Million INR | 9.4% |
| 2014 FY | 384 Million INR | 157.72% |
| 2014 Q1 | - INR | 0.0% |
| 2014 Q3 | 351 Million INR | 0.0% |
| 2013 FY | 149 Million INR | -16.76% |
| 2012 FY | 179 Million INR | 20.13% |
| 2011 FY | 149 Million INR | 136.51% |
| 2010 FY | 63 Million INR | -26.74% |
| 2009 FY | 86 Million INR | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Biocon Limited | 49.43 Billion INR | 95.176% |
| Blue Jet Healthcare Limited | 1.29 Billion INR | -83.695% |
| Concord Biotech Limited | 2.07 Billion INR | -14.689% |
| Dishman Carbogen Amcis Limited | 8.82 Billion INR | 72.986% |
| Jubilant Ingrevia Limited | 9.41 Billion INR | 74.663% |
| Lyka Labs Limited | 95.71 Million INR | -2391.694% |
| Panacea Biotec Limited | 1.77 Billion INR | -34.034% |
| Piramal Pharma Limited | 21.75 Billion INR | 89.039% |
| SMS Lifesciences India Limited | 812.1 Million INR | -193.682% |
| Supriya Lifescience Limited | 852.49 Million INR | -179.769% |
| TAKE Solutions Limited | 7.96 Million INR | -29862.312% |
| Zota Health Care Limited | 537.66 Million INR | -343.588% |